Biotech stocks rise on expectation of pro-industry FDA policy
user-generated· tech_stocks
Biotech stocks rise on expectation of pro-industry FDA policy
Market overview
Markets will price in a 15%+ increase in biotech valuations by December 2026, anticipating a pro-industry FDA stance under a new commissioner. This reflects pharma leaders' lobbying success in shaping regulatory tone.
tech_stocks prediction market
- Implied probability (Yes)
- 60%
Source: user-generated
More tech_stocks markets
- Amazon will invest in AI safety startups by Q1 2027 — 65% Yes
- S&P 500 outperforms MSCI World Index by 10% in 2027 — 68% Yes
- NVIDIA stock gains 20% by 2027 on AI hardware demand for tire-changing robots — 65% Yes
- Competitor AI models face similar 'jailbreaking' flaws within 6 months — 68% Yes
- U.S. AI industry attracts over $100B in venture funding by 2027 — 65% Yes
- Anthropic Mythos retains slight edge over GPT-5.5 in cybersecurity tests — 70% Yes
- S&P 500 outperforms MSCI EAFE by 8% in 2026 — 75% Yes
- Anthropic Mythos will outperform GPT-5.5-Cyber in simulated cyberattacks by Oct 2028 — 60% Yes
No one's made a Conviction call on this yet. Be the first to call it →
Loading…